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What is A Substance Use Disorder?
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) recently changed how
substance use disorders are defined and diagnosed. A substance use disorder is measured based on four
behavioral categories, impaired control, risky use, social impairment, pharmacological indictors
(tolerance and withdrawal) and is measured from mild to severe impairment (Kahan & Watt, 2017).
The difference between a substance use disorder and substance abuse problem is dependent on the
length of substance use. Long-term substance abuse problems are referred to as substance use
disorders and should be treated as serious mental illnesses (SAMHSA, 2017). It is observed that
persons with substance use disorders can live relatively normal lives and function adequately
enough to survive day to day. Addiction and dependence are components of a substance use
disorder. Addiction is when pursuit or, use of the substance begin to define the user’s life. Addictive
behaviors are the symptom of psychological disorders in combination with chemical dependence.

Introduction
Substance use is a complex public health issue that needs to be addressed through multiple
frameworks, and viewpoints. The cost of substance use on American productivity is estimated by the
National Institute on Drug Abuse (NIDA) to be $740 billion annually (NIDA, 2017). The nationwide
opioid epidemic has brought unprecedented attention to the public health issue of substance abuse.
The spotlight is currently on opioids, but it is important to keep other prominent illicit substances in
mind. The etiology of substance use is a complex issue that researchers are still trying to elucidate.
Two variables that have been found to have a high association with the development of a substance
use disorder are childhood trauma, and stress. These events are categorized as, adverse childhood
events (ACEs). ACEs are strong predictors of the lifetime risk of substance use and engagement in
risky behaviors (Dube et al., 2003). Substance use is also a known risk factor for engagement in risky
sexual behaviors. This resource guide will discuss the lifetime epidemiological risk of substance use.
This includes how substance use impacts a person’s risk of engagement in risky sexual behavior.
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Alcohol
Alcohol abuse is a pressing public health burden. The Centers for Disease Control and
Prevention estimate that alcohol kills over 80,000 people per year and cost the United States $249
billion in lost productivity in 2010 (CDC, 2018). Despite these statistics alcohol remains a staple of
American culture. Public health officials need to fight not only the addictive power of alcohol, but also
the power of alcohol advertising and cultural normalization. Social expectancies are an extremely
important tool in understanding how alcohol impacts the health of a user.
Research by George and Stoner (2000) describe how social expectancies shape the intentions of
users. They found that sexual behavior is greatly influenced by alcohol consumption among men and
women. Men and women perceive each other as more sexually attractive and sexually open when
consuming alcohol. Men also reported associating alcohol with sexual behaviors, which increase their
engagement in risky sexual behaviors. Based on large epidemiological surveys, such as the National
Epidemiologic Survey on Alcohol and Related Conditions, men aged 18-25 have the highest risk of
alcohol use disorder (AUD) (Delker, Brown, & Hasin, 2016).
The risk among men differs between racial groups as well; white males having the highest
prevalence of alcohol consumption, especially older white men. Despite the high prevalence of alcohol
consumption among white males, the highest prevalence of AUD is among Native Americans (Delker et
al., 2016; Sarche & Spicer, 2008). The rates of AUD among Native Americans are high in part due to their
cultural history of alcohol and tobacco use. Tobacco being used as currency was common practice
among Native American tribes before European colonization. European colonization brought trade in
the form of alcohol for tobacco. As European colonization increased, trade and the rate of alcohol
consumption increased along with it. As a result of this, Native Americans have a very high prevalence of
alcoholism.
The pharmacology of alcohol makes recovery from AUD very difficult. The neurotransmitters of
a person with AUD no longer function normally (Figure 1). Alcohol indirectly binds with the gammaaminobutyric acid (GABA) receptors where its action mimics GABA (Figure 2). The GABA receptors are
found throughout the central nervous system and are major inhibitory neurotransmitters (Olsen &
DeLorey, 1999). Alcohol inhibits glutamate, interferes with glucose regulation, and causes the
neurotransmitters dopamine and serotonin to be released (Banerjee, 2014). Dopamine and serotonin
are responsible for feelings of pleasure, reward seeking, motivation, and several other crucial functions.
Chronic alcohol consumption can create a physical dependence in the brain that alters brain chemistry
(Clapp, Bhave, & Hoffman, (2008). (Figure 3). In addition, inhibition of the GABA receptors results in
reduced anxiety, which prompts the user to seek alcohol when experiencing stress or trauma (Clapp et
al., 2008). Once the brain has created new pathways, cessation of use becomes incredibly difficult.
When someone with AUD or a physical dependence on alcohol stops consuming it, they experience
withdrawal (Banerjee, 2014). Withdrawal is the result of an absence of vital neurotransmitters,
dopamine, serotonin, and GABA (Clapp et al., 2008). The user’s brain has stopped producing these
transmitters on its own because alcohol used to provide them (Figure 4). When someone is going
through alcohol withdraw, they can experience withdrawal symptoms such as, anxiety, depression,
mood swings, fever, sweating, irritability, nausea, insomnia and delirium (Medlineplus, 2019). These
symptoms can be life threatening and are the reason that relapse is so common among AUD patients.
Due to the high prevalence of AUD there are many resources available to help users get into recovery.
Throughout American history there have been social movements to ban the use of alcohol
because of its destructive nature. Federal action against alcohol use was taken by the passage of
prohibition, which was started by the ratification of the 18th amendment of the United States
Constitution. The 18th amendment made the sale and production of intoxicating liquors illegal (History,
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2009). The prohibition movement, as it would later be called, was largely led by women, due to the
destruction alcohol abuse often brings to families (History, 2009). At first prohibition was moderately
successful in reducing alcohol related arrests and crime (History, 2009). Enforcement proved to be
difficult though and depended largely on how sympathetic communities were to the new laws (History,
2009). Illegal alcohol manufacturing, known as bootlegging, and speakeasys (clubs where alcohol was
illegally sold) began to create an impressive black market for alcohol (History, 2009). Prohibition also
disproportionally impacted the poor and working class because illegal alcohol was expensive, compared
to the more well off who could easily pay the increased prices. Prohibition came to an end in 1933 under
President Roosevelt. He used the legalization of alcohol to spur job creation during the great depression
and took advantage of the vast cultural desire for legalization. Despite the failure of prohibition, the
main issue as to why many in the temperance movement wanted to outlaw it was ahead of its time.
Current research on ACEs brought on by alcoholic parents provide robust scientific support for
the impact that alcoholism has on children, and families (Dube et al., 2003). There are several
government resources, such as the Substance Abuse and Mental Health Services Administration
(SAMHSA) national helpline that is available on their website. Government services such as Medicare
and Medicaid will cover treatment for AUD among qualified rehab centers. The Affordable Care Act also
opened many opportunities for treatment for users who opt into it. Additional federal and state
recovery and prevention organizations and program can be found in the substance use resources listed
at the end of this resource guide.

Figure 1. An illustration of how healthy neurons function.
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Source: https://www.drugabuse.gov/news-events/nida-notes/2017/03/impacts-drugsneurotransmission

Figure 2. How the brain’s glutamate system reacts to alcohol consumption.
Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm

Figure 3. Areas of the brain that are effected by alcohol use.
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Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm

Figure 4. How the brain’s glutamate system functions during alcohol withdrawal.
Source: https://pubs.niaaa.nih.gov/publications/arh314/310-339.htm
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Opiates
The United States has experienced three waves of mass opiate addiction since the 19th
century (Dark Paradise, 2001). The death toll from overdose caused by any opiate has reached
almost 400,000 since 1997, and of the 70,200 overdose deaths in 2017 68% involved an opiate
(Scholl, Seth, Kariisa, Wilson, & Baldwin, 2018; Opioid, 2018). Currently synthetic opioids, like
fentanyl and illegally manufactured fentanyl analogs are the driving force of overdose deaths
(Opioid, 2018). The incidence of human immunodeficiency virus (HIV) and other sexually
transmitted diseases (STDs) in the United States has been rising alongside the opioid epidemic and is
an urgent public health problem. Recreational drug use has been linked to an increased risk of
engaging in risky sexual behaviors and acquiring HIV or other STD's (Mitchell & Potenza, 2014).
Research has found that drug users are more likely to engage in risky behavior, such as impulsivity
and sensation seeking (Celentano, Latimore, & Mehta, 2008).
All opioids interact with the endogenous opiate system. Researchers have found that there
are three types of opioid receptors, mu, kappa, and delta. The mu opioid receptors are the primary
target of opiates that are commonly abused (Figure 5). When the opioid binds to the mu receptors,
the brain produces the same biochemical reward response as experienced by normal everyday life
functions, such as eating or sex (Kosten & George, 2002). Figure 6 illustrates the areas of the brain
impacted by opiate use. Opioids are highly active in the mesolimbic reward system. The mesolimbic
system sends dopamine to the nucleus accumbens which causes feelings of pleasure. This chain
reaction caused by opiate use creates powerful reward pathways in the brain that can reactivate
and cause opiate craving when stimulated (Kosten & George, 2002). These new pathways in the
brain persist long after opiate use has stopped, and they can be triggered by intense stress or
environmental stimuli. The intense feelings of pleasure and wellbeing triggered in the nucleus
accumbens (NAc) by dopamine from the ventral tegmental area (VTA) creates a reward pathway in
the prefrontal cortex (PFC) that drives addictive behavior (Figure 6) (Kosten & George, 2002).
The phenomena of tolerance is when users must take increasing doses of the substance in
order to achieve the same pharmacological effect (Shenoy & Lui, 2018). Figure 7 illustrates how
tolerance for opiates builds. Tolerance is dangerous because the negative side effects of the opiates,
such as respiratory sedation begin to become stronger (Shenoy & Lui, 2018). A user who develops
tolerance becomes susceptible to developing both physical and psychological dependence (Shenoy
& Lui, 2018). Physical dependence on opiates will occur from any prolonged use of the drug, even in
clinical settings. The time it takes to develop physical dependence varies from person to person
(Shenoy & Lui, 2018). Physical dependence is not the same as opiate addiction. Addictive behaviors,
such as drug seeking, doctor shopping, or taking more of the drug than needed begin to develop
when psychological dependence begins. Withdrawal is the major driver of opiate abuse disorder.
The physical pain and discomfort caused by opiate withdrawal enhances the psychological drive to
use the drug, this is known as opiate craving (figure 7). Opiate cravings felt during withdrawal are
powerful influences on behavior and actions the user engages in. Opiate withdrawal has proven to
be a difficult condition due to the complexity presented by truncated variants in the G-coupled
opioid receptors, and heterogeneity in receptor interactions (Burma, Kwok, & Trang, 2017). When a
user begins to experience opiate withdrawal, the nervous system enters a state of hyperexcitability.
The hyperexcitability of the nervous system during opiate withdrawal causes immense anxiety,
gastrointestinal distress, restlessness, insomnia, and hyperhidrosis (Burma et al., 2017).
Noradrenaline which was once suppressed by the opiate use enters a state of enhanced
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noradrenergic tone, causing withdrawal symptoms (Burma et al., 2017). The drive to alleviate
symptoms of withdrawal often lead users to seek street opiates, which further amplifies the
addictive cycle (Burma et al., 2017). There is another type of opiate withdrawal that is lesser known
but, is beginning to gain the attention of the medical community. Post -acute withdrawal syndrome
(PAWS) is a phenomenon that occurs after the acute phase withdrawal from a substance (Crane,
2018). PAWS is most commonly seen in amphetamine, alcohol, benzodiazepine, and opiate abusers
who had used the drugs for prolonged periods (Crane, 2018). The symptoms of PAWS are not as
intense as the symptoms during acute withdrawal, but they can last much longer (Crane, 2018). One
of the major symptoms of PAWS is anhedonia, which is the inability to feel pleasure from typical life
stimuli. Along with anhedonia PAWS sufferers also experience insomnia, depression, brain fog, and
difficulty concentrating (Crane, 2018). PAWS is likely a major driver of relapse due to the prolonged
period the symptoms occur. Users can begin to experience hopelessness because even though they
have weathered acute withdrawal and stopped their drug abuse, they still feel the effects months
after they had ceased use (Crane, 2018). When subjected to the symptoms of PAWS for a prolonged
period, drug use begins to seem like the only way to feel anything again. PAWS will typically subside
if the user stays sober and practices healthy life habits. The amount of time a user will experience
PAWS and the likelihood that they will experience it depends on what substance was used and for
how long (Crane, 2018). Opiate withdrawal also is the main driver in amplifying the risk user’s incur
during opiate use.
The effect of opiates on the brain creates intense euphoria but is also sedating. Compared
to amphetamines both substances cause large amounts of dopamine to be released but
amphetamines increase the risk of engagement in risky sexual behaviors while the users are “high”
on the substance. Amphetamines increase energy and lower inhibitions, while opiates sedate and
relax the user. Opiates also suppress testosterone in both men and women leading to a general
reduction in libido both while using opiates and when in withdrawal (Le-Merrer, Becker, Befort, &
Kieffer, 2009). User’s increase their risk of contracting HIV/STDs when they engage in trading sexual
acts for opiates or engage in sex work for money to support their addiction to opiates. Opiates and
amphetamines are often used together during circuit parties, which are gatherings where men who
have sex with men (MSM) engage in social activities and often group drug use/sexual activities. In
this population it is common to trade sexual favors for drugs and to use drugs to enhance sexual
experiences (chemsex). These behaviors expose MSM to an increased risk of acquiring HIV/STDs,
especially when Intravenous (IV) drug use is common (Colfax et al., 2001). Researchers have seen
that users who injected prescription opioids are more likely to report being HIV-positive and have
had previous STD diagnoses (Jaeger-Woods, Jaeger, Donenberg, & Wilson, 2013). Women are also at
an increased risk of being taken advantage of sexually during opiate withdrawal. Women who use
opioids were subjected to increased rates of sexual violence when compared to women who did not
use opioids (Mateu-Gelabert, Guarino, Jessell, & Teper, 2015).
Opioid abuse disorder is particularly difficult to recover from due to the impact that opiates
have on the user’s brain. Long-term opiate use changes the neuropathways in the user’s brain so
that even when they have stopped using, they will experience cravings for the substance. Complete
recovery is possible from long-term opiate use, but recovery can take years. Due to the rise in opiate
overdose deaths many new treatment tools and modalities are being made available for any user
who is willing to ask for help. One of the most effective ways to fight opiate addiction is with
medication assisted treatment. Medication assisted treatment include substituting illicit opioid use
with prescription opiate use, coupled with behavioral coaching and psychotherapy. Opiate users can
slowly taper down their prescribed opiates while they learn the deep psychological drivers of their
addictive behavior. Traumatic childhood experiences, or ACEs are strong predictors of lifetime drug
abuse and opiate users who have experienced these events need to learn how to cope and heal
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from them in beneficial ways (Dube et al., 2003). Medication assisted therapy is useful because it
enables the opiate user to have a stable emotional state while processing these traumatic
experiences, reducing the likelihood of relapse. Detox programs and 12-step programs are also
available to help opiate users stop their drug use and learn why they began to use the drugs in an
unhealthy manner. Several government organizations like the United States department of Health
and Human Services, National Institute on Drug Abuse, and the National Institute of Health have
federally funded programs to help people who are suffering from opiate use disorder.

Figure 5. Morphine activates the opioid receptors, reduces the release of y-amniobutyric acid
(GABA) and causes excess dopamine to be released.
Source: https://www.the-scientist.com/cover-story/pain-and-progress-38043
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Figure 6. Opioids stimulate the ventral tegmental area (VTA) releasing dopamine into the
nucleus accumbens (NAc) which causes intense feelings of pleasure and satisfaction. A feedback loop of
this reward mechanism then forms between the prefrontal cortex (PFC) and VTA pushing the user to
pursue this feeling over anything else.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851054/
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Figure 7. The mechanism of opioid tolerance and withdrawal.
Source: https://medium.com/dr-ming-kao/opioid-tolerance-dependence-and-withdrawal821ef0ec7dd7
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Amphetamines
The incidence of amphetamine drug use has increased throughout the United States over the
last decade (Piper et al., 2018). Amphetamine overdose deaths are the second most common type of
drug overdose death, behind opiates (NIH). One reason that there has been an increase in amphetamine
usage over the past decade is because of the class of drugs used for the front-line treatment of ADHD.
Adderall, Ritalin, Vyvanse, Concerta, Dexedrine, and Focalin are common brand names for
amphetamine-based prescription ADHD treatment. Methamphetamine is a class of amphetamine that is
nearly exclusively used for recreational purposes and is the drug of choice for many amphetamine
addicts. Illicit methamphetamine use is not nearly as prevalent as illicit opioid use and has a strong
regional component. The 2018 National Drug Early Warning System (NDEWS) reported that admission to
treatment centers for methamphetamine use west of the Mississippi river (12-29%) was significantly
higher than admissions east of the Mississippi (<1%), except for the Atlanta metro area which reported
11% of treatment admissions for methamphetamine use (Artigiani, Hsu, McMandlish, & Wish, 2018).
Amphetamine use is a particularly salient statistic to note during the opiate epidemic because it is
frequently the drug of choice for opiate users who are also polysubstance users. Users will combine
opiates and methamphetamine and inject them (often referred to as speedball or goofball). The result is
one of the most powerful and deadly forms of illicit drug combinations; many high-profile celebrity
deaths have been from this combination.
Amphetamine drugs are highly addictive due to their pharmacology (figure 8,9). Amphetamines
primarily act on dopamine receptors, where they increase extracellular dopamine by prolonging
dopamine receptor signaling in the striatum (Calipari & Ferris, 2013). Dopamine is a vital
neurotransmitter for proper executive functioning, emotional salience, motivation, and reward
reinforcement (Calipari & Ferris, 2013). Amphetamines are useful for ADHD treatment because current
research suggests that a lack of dopamine negatively influences a person’s ability to stay focused,
motivated, and maintain good executive function. The increase in dopamine is useful for alleviating
these symptoms, but the impact that these drugs have on reward salience, and motivation can lead to
dependence and addiction (figure 9). Even when amphetamine drugs are taken as prescribed, they can
change the brain’s ability to produce dopamine naturally. When this change occurs, a person will
experience withdrawal effects if they stop taking their medication. Withdrawal can then lead to drug
seeking behavior and can push a person to use methamphetamine. Methamphetamine and prescription
amphetamines have the same effect on the brain, but methamphetamine is much stronger in the effects
than prescription. The effects of methamphetamine are extremely potent that addiction can occur after
the first use, especially if it is administered intravenously (IV).
Methamphetamine use is a risk factor for engagement in risky sexual behavior. The incidence of
methamphetamine use is high in certain populations. Men who have sex with men (MSM), chemsex
users (enhancement of sex through substances), polysubstance users, and opiate users all have a higher
incidence of methamphetamine use than the general public (SAMHSA, 2018). Injection drug users who
shoot methamphetamine are at an increased risk for contracting HIV, or hepatitis B or C (NIH, 2019).
MSM who participate in methamphetamine injection drug use (IDU) are more likely to engage in risky
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sexual behaviors, facilitated by methamphetamine use. When methamphetamine is used intravenously
it causes intense euphoria and decreased inhibition, which lowers the rate of condom use among MSM
(Bull, Pper, & Rietmeijer, 2002). The NIH has found that methamphetamine users are more likely than
any other group of substance abusers to contract HIV due to two factors; needle sharing, and the effect
that methamphetamine has on libido and reward processing (NIH, 2019). Methamphetamine users who
already had HIV were found to have worse outcomes than non-users and users who were taking highly
active antiretroviral therapy (HAART) were more likely to develop AIDS (Ellis et al., 2003; Fairbairn et al.,
2011).

Figure 8. Illustration of a neurotransmitter under the influence of cocaine. Cocaine blocks
dopamine re-uptake resulting in excess levels of dopamine in the synapse.
Source: http://universe-review.ca/R10-16-ANS01.htm

Rotoloni 17

Figure 9. This illustration shows how the neurotransmitters react to amphetamines causing a
surge of dopamine and noradrenaline in the synaptic cleft.
Source: https://forensictoxicology-blog.tumblr.com/post/43936999014/mechanism-of-action
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Cannabis
Cannabis or marijuana is the most commonly used illicit substance in the United States. A 2015
report from the National Survey on Drug use and Health reported that nearly 22.2 million people had
used marijuana in the last month (SAMSHA, 2018). The monitoring the future survey (MTF) reported
that 43.6% of 12th graders had reported trying marijuana at least once in their lifetime. The National
Survey on Drug use and Health showed that 22.1% of people aged 18 through 25 had used marijuana in
the past month (NIH, 2019). Marijuana’s complex legal status makes it unique when compared to the
other substances in this resource guide. Marijuana has been federally illegal in the United States since
the Controlled Substances Act was passed in 1970 by Richard Nixon. Since then the legality of marijuana
use has repeatedly been a subject of controversy. One of the main reasons for this legal battle is over
the legitimacy of marijuana use as a medicine. The changing legal status of marijuana has made
understanding the impact that it has on the brain a pressing research issue. This is especially important
due to adolescent usage and the impact on engagement in risky behaviors that marijuana use may
contribute to.
The active components in marijuana are known as cannabinoids and they interact with the
bodies endocannabinoid system. The most well-known cannabinoid is delta-9-tetrahydrocannabinol or
THC. This is a psychoactive cannabinoid that is responsible for the ‘high” feeling that users report after
consumption of marijuana. The cannabinoid system regulates many important functions like mood,
appetite, and pain-suppression (figure 10). Marijuana’s ability to inhibit pain is a major driver in the
effort to allow chronic pain patients access to medical marijuana as an alternative to opiate medication.
There are two types of cannabinoid receptors cannabinoid receptor 1 (CB1) and cannabinoid receptor 2
(CB2) (Zou & Kumar, 2018). Receptors CB1 and CB2 are members of the G-protein family. The G-protein
coupled family of neuroreceptors are abundant through many vital systems in the body and brain (figure
13). These findings have led scientists to believe that humans evolved the ability to experience
cannabinoids. There are two main types of canabinoids: Phyto-cannabinoids (cannabinoids that come
from the plant) THC is an example of this, and endogenous cannabinoids which are formed in the body.
Examples of endogenous cannabinoids are N-arachidonoylethanolamine or anandamide (AE) or 2arachidonoylglycerol (2-AG), purified, and synthetic (NIH, 2018). There is emerging research that
suggests cannabinoids can have an impact on fertility, but research is mixed. Gorzalka and Dang (2012)
found that cannabis use heightened male and female sexual proceptivity. They found that as the
amount of cannabis increased, males began to experience a drop in sexual proceptivity while females
remained similar with a slight rise (Gorzalka, Hill, & Chang, 2010). Gorzalka and Dang (2012) theorized
that THC reduces testosterone and luteinizing hormone by binding to the cannabinoid receptors CB1
and CB2. Mimicking anandamine an endogenous cannabinoid (figure 11). This effect is more present in
men due to increased levels of testosterone (Gorzalka et al., 2010; Gorzalka & Dang, 2012). It is difficult
for researchers to further study cannabis due to the changing legal status of the substance.
The impact that cannabis has on risky sexual behavior is mediated by its legal status. Federally
cannabis is still listed as a schedule 1 substance and is illegal in the United States. States have voted and
decided to legalize both medicinal and recreational cannabis use. The distinction between medicinal and
recreational use differs between states. The distinction between legal and illegal is important to note
because the legality of a substance can impact the population that uses it. Research has found that the
impact cannabis has on sexual risk behavior is mediated by the social expectancies the user experiences.
(Stoner, 2018). Hendershot et al., (2010) investigated this phenomenon and found that among
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adolescents' strong sexual expectancies that were associated with cannabis use predicted an increase in
the user’s engagement in risky sexual behavior. The impact that cannabis use has depends also on how
regularly it is used, if it is used alone or with other substances, and the type of association being
researched. (Stoner, 2018). Brodbeck, Matter, and Moggi (2006) found that cannabis users aged 16-24
who reported at least weekly cannabis use were more likely to engage in risky sexual behavior than their
peers who did not use cannabis. Polysubstance use that included cannabis also was found to impact a
person’s likelihood of engaging in risky sexual behavior within the pat 12 months (Swartzendruber,
Sales, Brown, DiClemente, Rose, 2016). Event-Level studies of the impact on cannabis use showed that,
among adolescents, cannabis use was associated with an increase in risky sexual behaviors, but among
adults no association was found (Stoner, 2018). Research by Walsh, Fielder, Carey and Carey (2014)
supports this finding. They found that among the college aged women in their study cannabis use was
not associated with an increase in risky sexual behavior. The mixed results of these studies show that
much more research on cannabis’ impact on risky sexual behavior is needed. Currently, researchers
believe that the impact cannabis has on a person’s risk of engagement in risky sexual behavior is
dependent on the social expectancies in which cannabis is being used (Stoner, 2018).

Figure 10. Brain structures in which the endocannabinoid system is active.
Source: http://headsup.scholastic.com/students/the-science-of-marijuana
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Figure 11. The similarity of the brain’s natural chemical anandamide and THC from cannabis.
Source: https://www.drugabuse.gov/publications/research-reports/marijuana/how-doesmarijuana-produce-its-effects

Figure 13. Illustration of how THC impacts the body's ability to produce neurotransmitters.
Source: https://www.the-scientist.com/infographics/infographic--how-exposure-to-cannabis-inutero-affects-development-65266
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Trend Graphics of Substance Use in the United
States

Graphic 1: Results from the 2017 NSDUH on illicit drug use.
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf

Rotoloni 22

Graphic 2: Reports of alcohol use disorder given from the 2017 NSDUH
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf

Graphic 3: Break down of prescription pain reliever misuse among age categories.
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf
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Graphic 4: Precentage of each type of opiate misused the previous year among respondents to the
NSDUH.
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf

Graphic 5: Marijuana use in the past year broken down by age group.
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Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf

Graphic 6: Prevalence of cannabis use among young adults.
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf

Graphic 7: Prevalence of methamphetamine use among age groups.
Source: https://www.samhsa.gov/data/sites/default/files/nsduh-ppt-09-2018.pdf
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Substance Abuse Resources
Alcohol

Opiates

Cannabis

Amphetamines

CADCA - Anti-Drug Coalitions of America
NIAAA - National Institute on
Alcohol Abuse and Alcoholism
AA - Alcoholics Anonymous
ICCPUD - Interagency Cordination
Commity on the Prevention of Underage Drinking
NASADAD - National Association of State
Alcohol and Drug Abuse Directors
NTN - National Treatment Network
NCADD - National Council on Alcohol and
Drug Dependence
NPN - National Prevention Network
NYRF - National Youth Recovery
Foundation
YPR - Young People in Recovery
NIH (HEAL) - National Institute of Health
Helping to End Addiction Long-Term
HHS - Health and Human Services Opioids
page
NA - Narcotics Anonymous
SMART Recovery - 4 point program to
help people overcome addictive behaviors
NAR-ANON - Support for friends and
family of narcotic addicts
NIDA - National Institute on Drug Abuse
Prevention Tools
NIH - National Institute of Health
SAMHSA - Substance Abuse and Mental
Health Services Administration
MA - Marijuana Anonymous
Crystal Meth ANON - Community
support
for crystal meth addicts
ACA - American Addiction Centers
SAMHSA - Substance Abuse and Mental
Health Services Administration
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